AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26149937 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous ureteroscopic lithotripsy and contralateral percutaneous nephrolithotomy
Number of subjects: 103
Study 26149937 — intervention group
Group type: COMPARATOR
Intervention: Staged ureteroscopic lithotripsy followed by staged percutaneous nephrolithotomy
Number of subjects: 103
Study 24013574 — intervention group
Group type: COMPARATOR
Intervention: Dextromethorphan (DM) alone at 60 mg on day 1
Number of subjects: 0
Study 24013574 — intervention group
Group type: COMPARATOR
Intervention: Panobinostat at 20 mg alone on days 3 and 5
Number of subjects: 0
Study 24013574 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) and panobinostat co-administered on day 8
Number of subjects: 0
Study 20700674 — intervention group
Group type: EXPERIMENTAL
Intervention: Medially conforming ball-and-socket design
Number of subjects: 82
Study 20700674 — intervention group
Group type: COMPARATOR
Intervention: Posterior-stabilized total knee prosthesis
Number of subjects: 82
Study 19110787 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary aspiration with the Export aspiration catheter followed by stenting
Number of subjects: 249
Study 19110787 — intervention group
Group type: COMPARATOR
Intervention: Conventional stenting without primary aspiration
Number of subjects: 249
Study 17227263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 70
Study 17227263 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 70
Study 14584555 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with frontal lobe injuries
Number of subjects: 2
Study 14584555 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2
Study 14584555 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with injuries centered in the frontal poles
Number of subjects: 2
Study 14584555 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lesions restricted to dorsolateral prefrontal cortex
Number of subjects: 2
Study 10929919 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 125
Study 10929919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 125
Study 10929919 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 125
Study 10929919 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 125
Study 10929919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 125
Study 8814419 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ) 150 mg per day for 6 months
Number of subjects: 8
Study 1306815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (active treatment group, 45 patients)
Number of subjects: 100
Study 1306815 — intervention group
Group type: COMPARATOR
Intervention: Control group (42 patients)
Number of subjects: 100
Study 2867800 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg thiotepa instillation at the time of primary treatment
Number of subjects: 417
Study 2867800 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillations of thiotepa at 3‐monthly intervals for a year
Number of subjects: 417
Study 2867800 — intervention group
Group type: COMPARATOR
Intervention: No instillation (Control group)
Number of subjects: 417
Study 31213079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 0
Study 29767684 — intervention group
Group type: EXPERIMENTAL
Intervention: PI monotherapy
Number of subjects: 609
Study 29767684 — intervention group
Group type: COMPARATOR
Intervention: Standard tritherapy
Number of subjects: 609
Study 29767684 — intervention group
Group type: EXPERIMENTAL
Intervention: PI monotherapy receiving DRV/r
Number of subjects: 609
Study 29767684 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline USVL<1 copy/mL
Number of subjects: 609
Study 29767684 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline CD4
Number of subjects: 609
Study 27321324 — intervention group
Group type: EXPERIMENTAL
Intervention: Welltang intervention group
Number of subjects: 100
Study 27321324 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual standard of care)
Number of subjects: 100
Study 25134972 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg BID
Number of subjects: 98
Study 25134972 — intervention group
Group type: COMPARATOR
Intervention: Propafenone 150 mg TID
Number of subjects: 98
Study 22665124 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 10% of energy from pistachios (1 serving per day)
Number of subjects: 28
Study 22665124 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 20% of energy from pistachios (2 servings per day)
Number of subjects: 28
Study 22665124 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet (25% total fat and 8% saturated fat)
Number of subjects: 28
Study 20447572 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3605
Study 20447572 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics
Number of subjects: 3605
Study 20447572 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR
Number of subjects: 3605
Study 20447572 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher blood pressure
Number of subjects: 3605
Study 20447572 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower hemoglobin levels
Number of subjects: 3605
Study 17619081 — intervention group
Group type: EXPERIMENTAL
Intervention: C(18)-ceramide levels in HNSCC tumors
Number of subjects: 45
Study 17619081 — intervention group
Group type: EXPERIMENTAL
Intervention: C(16)-, C(24)-, C(24:1)-ceramides levels in HNSCC tumors
Number of subjects: 45
Study 17619081 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall stages of primary HNSCC tumors
Number of subjects: 45
Study 17136931 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education programme
Number of subjects: 639
Study 12065927 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone plus letrozole
Number of subjects: 0
Study 12065927 — intervention group
Group type: COMPARATOR
Intervention: Testosterone plus placebo
Number of subjects: 0
Study 12065927 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study 10527197 — intervention group
Group type: EXPERIMENTAL
Intervention: AngioJet F105 rheolytic catheter
Number of subjects: 153
Study 10527197 — intervention group
Group type: COMPARATOR
Intervention: Surgical thrombectomy
Number of subjects: 153
Study 8833947 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1-antitrypsin level in patients with melanoma of the choroid
Number of subjects: 35
Study 8833947 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 35
Study 1385929 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg (5 mg for patients ≤30 kg)
Number of subjects: 41
Study 1385929 — intervention group
Group type: COMPARATOR
Intervention: Astemizole 2 mg/10 kg body weight
Number of subjects: 41
Study 6502473 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid regimen administered for three full days
Number of subjects: 9
Study 6502473 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline therapy with antacids
Number of subjects: 9
Study 6502473 — intervention group
Group type: COMPARATOR
Intervention: Control (theophylline therapy without antacids)
Number of subjects: 9
Study 31674861 — intervention group
Group type: EXPERIMENTAL
Intervention: OMDI 0.0025% (1 drop in both eyes for 7 days)
Number of subjects: 14
Study 30291402 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-nicotine-content cigarettes (VLNCCs; 1 mg nicotine/g tobacco)
Number of subjects: 118
Study 30291402 — intervention group
Group type: COMPARATOR
Intervention: Normal-nicotine-content cigarettes (NNCCs; 16 mg/g)
Number of subjects: 118
Study 27765120 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI≥28.0 kg/m2
Number of subjects: 3043
Study 27765120 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gains in subjects with baseline BMI<24.0 kg/m2
Number of subjects: 3043
Study 27765120 — intervention group
Group type: COMPARATOR
Intervention: Stable weight (BMI change of -0.05 to +0.05 per year)
Number of subjects: 3043
Study 24214217 — intervention group
Group type: EXPERIMENTAL
Intervention: sipoglitazar (8, 16, 32, or 64 mg once daily; 16 or 32 mg twice daily)
Number of subjects: 780
Study 24214217 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg once daily)
Number of subjects: 780
Study 24214217 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 780
Study 22377180 — intervention group
Group type: COMPARATOR
Intervention: lamotrigine
Number of subjects: 0
Study 22377180 — intervention group
Group type: COMPARATOR
Intervention: gabapentin
Number of subjects: 0
Study 22377180 — intervention group
Group type: COMPARATOR
Intervention: topiramate
Number of subjects: 0
Study 20064020 — intervention group
Group type: EXPERIMENTAL
Intervention: Grounding for 40 minutes
Number of subjects: 28
Study 20064020 — intervention group
Group type: COMPARATOR
Intervention: Sham grounding for control session
Number of subjects: 28
Study 17386379 — intervention group
Group type: COMPARATOR
Intervention: Exercise treadmill ECG (ETT)
Number of subjects: 457
Study 17386379 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT myocardial perfusion imaging (MPI)
Number of subjects: 457
Study 16282930 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate (MCC) vaccine
Number of subjects: 62
Study 11865832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 2400 mg (four 600‐mg tablets daily) for 10 days
Number of subjects: 20
Study 11865832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10192613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 78
Study 10192613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 8001393 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophosphoryl lipid A (20 micrograms/kg)
Number of subjects: 44
Study 8001393 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophosphoryl lipid A
Number of subjects: 44
Study 8001393 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 44
Study 1700873 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid (hydroxy ethyl starch) and electrolyte solution (group COL)
Number of subjects: 16
Study 1700873 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid fluid alone (group CR)
Number of subjects: 16
Study 1700873 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 7019638 — intervention group
Group type: EXPERIMENTAL
Intervention: MAF (melphalan, adriamycin, 5‐fluorouracil)
Number of subjects: 40
Study 7019638 — intervention group
Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, adriamycin, 5‐fluorouracil)
Number of subjects: 40
Study 31873746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir LA 400 mg + Rilpivirine LA 600 mg IM every 4 weeks
Number of subjects: 18
Study 31873746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir LA 600 mg + Rilpivirine LA 900 mg IM every 8 weeks
Number of subjects: 18
Study 30869168 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 0
Study 30869168 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 0
Study 30869168 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg
Number of subjects: 0
Study 30869168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28576736 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (200,000 international units)
Number of subjects: 20
Study 28576736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27382686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure adenoidectomy
Number of subjects: 150
Study 27382686 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with partial tonsillectomy
Number of subjects: 150
Study 27382686 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with total tonsillectomy
Number of subjects: 150
Study 27382686 — intervention group
Group type: COMPARATOR
Intervention: All surgical procedures
Number of subjects: 150
Study 25082923 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive inspiratory muscle training (RIMT)
Number of subjects: 40
Study 25082923 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation care
Number of subjects: 40
Study 22008041 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 203
Study 22008041 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance
Number of subjects: 203
Study 22008041 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection treatment
Number of subjects: 203
Study 22008041 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 203
Study 19461565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 60
Study 19461565 — intervention group
Group type: COMPARATOR
Intervention: Control (lidocaine only)
Number of subjects: 60
Study 17608965 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Sonda (LTS)
Number of subjects: 100
Study 17608965 — intervention group
Group type: COMPARATOR
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 100
Study 14999237 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of the International Prostate Symptom Score (IPSS) questionnaire.
Number of subjects: 150
Study 14999237 — intervention group
Group type: COMPARATOR
Intervention: Physician administration of the International Prostate Symptom Score (IPSS) questionnaire.
Number of subjects: 150
Study 11260005 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g-1 ointment plus UVB phototherapy
Number of subjects: 104
Study 11260005 — intervention group
Group type: COMPARATOR
Intervention: Vehicle plus UVB phototherapy
Number of subjects: 104
Study 9554807 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan, 50 mg for 14 days
Number of subjects: 19
Study 9554807 — intervention group
Group type: COMPARATOR
Intervention: placebo for 14 days
Number of subjects: 19
Study 7748145 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g one hour before breakfast and dinner)
Number of subjects: 43
Study 7748145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3058398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate ointment (0.1 percent), applied once daily
Number of subjects: 0
Study 3058398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate cream (0.1 percent), applied once daily
Number of subjects: 0
Study 3058398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate ointment and cream (0.1 percent)
Number of subjects: 0
Study 3058398 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide ointment (0.025 percent), applied three times daily
Number of subjects: 0
Study 3058398 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide ointment (0.1 percent), applied twice daily
Number of subjects: 0
Study 3058398 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide cream (0.025 percent), applied three times daily
Number of subjects: 0
Study 3058398 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide cream (0.1 percent), applied twice daily
Number of subjects: 0
Study 31680378 — intervention group
Group type: EXPERIMENTAL
Intervention: Eshnan (500 mg, three tablets taken orally after each meal for 2 months)
Number of subjects: 126
Study 31680378 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three tablets taken orally after each meal for 2 months)
Number of subjects: 126
Study 29551324 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational outreach call, multisession telephone counseling, and assistance with obtaining nicotine replacement therapy
Number of subjects: 1938
Study 29551324 — intervention group
Group type: COMPARATOR
Intervention: Usual Veterans Administration smoking services
Number of subjects: 1938
Study 25657022 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (up to 2.5 mg three times daily)
Number of subjects: 18
Study 25657022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 25657022 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat plus sildenafil
Number of subjects: 18
Study 25657022 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat plus sildenafil (in long-term extension)
Number of subjects: 18
Study 23255783 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of immunoglobulin A antibodies to Epstein‐Barr virus capsid antigen and nuclear antigen‐1 by enzyme‐linked immunosorbent assay and indirect mirror examination in the nasopharynx and/or lymphatic palpation (IMLP)
Number of subjects: 28688
Study 23255783 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group screening
Number of subjects: 28688
Study 23255783 — intervention group
Group type: EXPERIMENTAL
Intervention: IMLP-positive group screening
Number of subjects: 28688
Study 21602759 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise
Number of subjects: 101
Study 21602759 — intervention group
Group type: COMPARATOR
Intervention: Passive modalities
Number of subjects: 101
Study 19551373 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 10 mg
Number of subjects: 0
Study 19551373 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 0
Study 19551373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19551373 — intervention group
Group type: COMPARATOR
Intervention: Herbal relaxant
Number of subjects: 0
Study 16505432 — intervention group
Group type: EXPERIMENTAL
Intervention: TEC (carboplatin-paclitaxel-epirubicin)
Number of subjects: 1282
Study 16505432 — intervention group
Group type: COMPARATOR
Intervention: TC (carboplatin-paclitaxel)
Number of subjects: 1282
Study 12494319 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EX)
Number of subjects: 34
Study 12494319 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 34
Study 11273392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sadness (active thought process)
Number of subjects: 2
Study 11273392 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood (control group)
Number of subjects: 2
Study 9065993 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) (n = 28)
Number of subjects: 60
Study 9065993 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) (n = 32)
Number of subjects: 60
Study 9065993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LMWH and UFH
Number of subjects: 60
Study 9065993 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐operative coagulation test results
Number of subjects: 60
Study 9065993 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐dimer and fibrinogen levels
Number of subjects: 60
Study 9065993 — intervention group
Group type: EXPERIMENTAL
Intervention: FIGO stage
Number of subjects: 60
Study 8457132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 90
Study 8457132 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (P)
Number of subjects: 90
Study 8457132 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (A)
Number of subjects: 90
Study 2873545 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol hydrochloride
Number of subjects: 16
Study 2873545 — intervention group
Group type: COMPARATOR
Intervention: 0.6% metipranolol hydrochloride
Number of subjects: 16
Study 30285811 — intervention group
Group type: EXPERIMENTAL
Intervention: Single use negative pressure wound therapy (sNPWT)
Number of subjects: 80
Study 30285811 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 80
Study 30285811 — intervention group
Group type: EXPERIMENTAL
Intervention: sNPWT
Number of subjects: 80
Study 25862143 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI group (two-core targeted biopsy guided by MRI/TRUS)
Number of subjects: 175
Study 25862143 — intervention group
Group type: COMPARATOR
Intervention: Control group (12-core random biopsy)
Number of subjects: 175
Study 25862143 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI group (two-core MRI/TRUS-TB)
Number of subjects: 175
Study 25862143 — intervention group
Group type: COMPARATOR
Intervention: Control group (12-core RB)
Number of subjects: 175
Study 24212478 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg 0.5% isobaric levobupivacaine
Number of subjects: 60
Study 24212478 — intervention group
Group type: COMPARATOR
Intervention: 15 mg 0.5% isobaric bupivacaine
Number of subjects: 60
Study 22087644 — intervention group
Group type: EXPERIMENTAL
Intervention: MI + CBT
Number of subjects: 27
Study 22087644 — intervention group
Group type: EXPERIMENTAL
Intervention: NDC + CBT
Number of subjects: 27
Study 22087644 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 27
Study 20471658 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping between two spaces with somewhat different perceptual features
Number of subjects: 0
Study 20471658 — intervention group
Group type: COMPARATOR
Intervention: Mapping between spaces with identical features
Number of subjects: 0
Study 20471658 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping between spaces with increased differences
Number of subjects: 0
Study 17201989 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 per cent methylene blue stain
Number of subjects: 28
Study 17201989 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 per cent methylene blue stain
Number of subjects: 28
Study 15837439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical trial of arthroscopic partial meniscectomy
Number of subjects: 88
Study 15837439 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects lacking strong preferences for treatment
Number of subjects: 88
Study 15837439 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with strong preferences for treatment
Number of subjects: 88
Study 15837439 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 88
Study 15837439 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 88